scispace - formally typeset
A

Azfar Zaman

Researcher at Newcastle University

Publications -  237
Citations -  8538

Azfar Zaman is an academic researcher from Newcastle University. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 40, co-authored 212 publications receiving 6835 citations. Previous affiliations of Azfar Zaman include Freeman Hospital & Newcastle upon Tyne Hospitals NHS Foundation Trust.

Papers
More filters
Journal ArticleDOI

Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis.

TL;DR: Preeclampsia is associated with a 4-fold increase in future incident heart failure and a 2-fold increased risk in coronary heart disease, stroke, and death because of coronary heart or cardiovascular disease.
Journal ArticleDOI

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.

TL;DR: In this article, the authors compared percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for the treatment of left main coronary artery disease.
Journal ArticleDOI

Thyroid hormones and cardiovascular disease

TL;DR: Accumulating evidence supports the association between abnormal thyroid function at the time of an acute myocardial infarction (MI) and subsequent adverse cardiovascular outcomes and the effect of thyroid hormone replacement therapy for reducing the risk of cardiovascular disease.
Journal ArticleDOI

Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification.

TL;DR: A combination of prolonged SAPD, advanced age, and male sex identifies patients at high risk for development of AF after CABG.
Journal ArticleDOI

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, +188 more
- 15 Sep 2018 - 
TL;DR: The GLOBAL LEADERS trial as discussed by the authors showed that ticagrelor, in combination with aspirin for 1 month, followed by ticaragrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.